AI Article Synopsis
- The human microbiota can affect health, and imbalances in it may contribute to neurological disorders like Alzheimer's and ALS.
- A specific probiotic strain, Lacticaseibacillus rhamnosus HA-114, has shown potential in protecting against neurodegeneration in models of ALS and Huntington's disease.
- This protective effect is linked to its fatty acid content and requires certain metabolic proteins, suggesting that improving lipid metabolism through this probiotic could help manage neurodegenerative conditions.
Article Abstract
The human microbiota is believed to influence health. Microbiome dysbiosis may be linked to neurological conditions like Alzheimer's disease, amyotrophic lateral sclerosis, and Huntington's disease. We report the ability of a probiotic bacterial strain in halting neurodegeneration phenotypes. We show that Lacticaseibacillus rhamnosus HA-114 is neuroprotective in C. elegans models of amyotrophic lateral sclerosis and Huntington's disease. Our results show that neuroprotection from L. rhamnosus HA-114 is unique from other L. rhamnosus strains and resides in its fatty acid content. Neuroprotection by L. rhamnosus HA-114 requires acdh-1/ACADSB, kat-1/ACAT1 and elo-6/ELOVL3/6, which are associated with fatty acid metabolism and mitochondrial β-oxidation. Our data suggest that disrupted lipid metabolism contributes to neurodegeneration and that dietary intervention with L. rhamnosus HA-114 restores lipid homeostasis and energy balance through mitochondrial β-oxidation. Our findings encourage the exploration of L. rhamnosus HA-114 derived interventions to modify the progression of neurodegenerative diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729297 | PMC |
| http://dx.doi.org/10.1038/s42003-022-04295-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lacticaseibacillus rhamnosus HA-114 and Bacillus subtilis R0179 Prolong Lifespan and Mitigate Amyloid-β Toxicity in C. elegans via Distinct Mechanisms.
J Alzheimers Dis
August 2024
Rosell Institute for Microbiome and Probiotics, Montreal, QC, Canada.
Background: Recent advances linking gut dysbiosis with neurocognitive disorders such as Alzheimer's disease (AD) suggest that the microbiota-gut-brain axis could be targeted for AD prevention, management, or treatment.
Objective: We sought to identify probiotics that can delay Aβ-induced paralysis.
Methods: Using C.
Background And Aim: Gut microbiota influences energy homeostasis in part through circulating hormones. Insulin-like growth factor-binding protein (IGFBP)-2 is a biomarker whose increase in systemic circulation is associated with positive effects on body weight and metabolism. In a recent clinical trial, probiotic HA-114 supplementation showed positive effects on eating behaviors and insulin resistance in overweight participants undergoing a weight-loss intervention.
View Article and Find Full Text PDFThe effects of probiotic supplements on oxidative stress and inflammation in subjects with mild and moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled study.
Inflammopharmacology
April 2024
Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
Through modulating effects on the gut-brain axis, probiotics are an effective adjuvant treatment for Alzheimer's disease (AD), one of our century's most important medical care challenges (Agahi et al. Front Neurol 9:662, 2018). This trial aimed to examine the effects of two different single-strain probiotics on oxidative stress and inflammation in patients with mild and moderate AD.
View Article and Find Full Text PDFEvidence of the Dysbiotic Effect of Psychotropics on Gut Microbiota and Capacity of Probiotics to Alleviate Related Dysbiosis in a Model of the Human Colon.
Int J Mol Sci
April 2023
NuGut Research Platform, School of Nutrition Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Growing evidence indicates that non-antibiotic therapeutics significantly impact human health by modulating gut microbiome composition and metabolism. In this study, we investigated the impact of two psychotropic drugs, aripiprazole and (S)-citalopram, on gut microbiome composition and its metabolic activity, as well as the potential of probiotics to attenuate related dysbiosis using an ex vivo model of the human colon. After 48 h of fermentation, the two psychotropics demonstrated distinct modulatory effects on the gut microbiome.
View Article and Find Full Text PDFFatty acids derived from the probiotic Lacticaseibacillus rhamnosus HA-114 suppress age-dependent neurodegeneration.
Commun Biol
December 2022
Département de Neurosciences, Université de Montréal, Montréal, QC, Canada.
Article Synopsis
- The human microbiota can affect health, and imbalances in it may contribute to neurological disorders like Alzheimer's and ALS.
- A specific probiotic strain, Lacticaseibacillus rhamnosus HA-114, has shown potential in protecting against neurodegeneration in models of ALS and Huntington's disease.
- This protective effect is linked to its fatty acid content and requires certain metabolic proteins, suggesting that improving lipid metabolism through this probiotic could help manage neurodegenerative conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!